Digital Transformation to Drive the Antibodies Contract Manufacturing Market

Posted by Steve Sharma on December 20th, 2021

As per Persistence Market Research’s latest industry analysis, the global antibodies contract manufacturing market was valued at US$ 3.87 Bn in 2020, and is expected to exhibit a high CAGR of close to 13% over the forecast period (2021–2031).

Rising prevalence cancer and infectious diseases is creating rapid development and commercialization need for biopharmaceutical therapeutics. Ultimately, rise in the prevalence of both conditions is expected to drive the need for biologics.

With advancements in contract solutions, leading CDMOs are focusing on the expansion of their integrated capabilities from molecule-to-finished product. The trend is significant as the acceleration of development and speed to market is becoming more crucial for biopharmaceutical and biologics developers.

Get Sample Copy of this Report@ https://www.persistencemarketresearch.com/samples/32933